Lee Scott Golden Sells 795 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Lee Scott Golden sold 795 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total transaction of $39,829.50. Following the completion of the transaction, the executive vice president now owns 77,856 shares of the company’s stock, valued at approximately $3,900,585.60. The trade was a 1.01 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Lee Scott Golden also recently made the following trade(s):

• On Tuesday, January 7th, Lee Scott Golden sold 810 shares of PTC Therapeutics stock. The stock was sold at an average price of $45.34, for a total value of $36,725.40.

PTC Therapeutics Stock Performance

Shares of PTC Therapeutics stock opened at $50.69 on Friday. The stock has a market cap of $3.91 billion, a P/E ratio of -8.53 and a beta of 0.62. The stock’s fifty day moving average is $46.67 and its 200 day moving average is $41.56. PTC Therapeutics, Inc. has a one year low of $24.00 and a one year high of $54.16.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on PTCT shares. Robert W. Baird upped their price target on PTC Therapeutics from $52.00 to $70.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. UBS Group upped their target price on shares of PTC Therapeutics from $47.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. The Goldman Sachs Group lifted their price target on shares of PTC Therapeutics from $32.00 to $42.00 and gave the stock a “sell” rating in a research note on Wednesday, December 4th. StockNews.com downgraded shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Finally, Morgan Stanley raised shares of PTC Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $45.00 to $67.00 in a research report on Friday, December 13th. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $58.85.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. grew its stake in shares of PTC Therapeutics by 7.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 706,730 shares of the biopharmaceutical company’s stock valued at $26,220,000 after acquiring an additional 47,902 shares during the period. Two Sigma Advisers LP lifted its holdings in PTC Therapeutics by 10.3% during the third quarter. Two Sigma Advisers LP now owns 429,842 shares of the biopharmaceutical company’s stock valued at $15,947,000 after purchasing an additional 40,300 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of PTC Therapeutics in the third quarter worth approximately $698,000. Vontobel Holding Ltd. purchased a new stake in shares of PTC Therapeutics in the fourth quarter worth $521,000. Finally, Quest Partners LLC increased its stake in shares of PTC Therapeutics by 433.9% in the third quarter. Quest Partners LLC now owns 22,359 shares of the biopharmaceutical company’s stock worth $830,000 after purchasing an additional 18,171 shares in the last quarter.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.